Toleranzia reports results from successful in-vivo pharmacological studies

8 July - 2016

Toleranzia AB (“Toleranzia”) hereby announces that two different in-vivo pharmacological studies concerning routes of administration and dose-response for Toleranzia’s tolerogen, have been carried out during the spring with good results. The results of both studies provide important guidance for the preclinical toxicology and safety pharmacology studies that are planned to start during Q4, 2016.

Regarding the possible routes of administration for Toleranzia’s tolerogen, the clinical efficacy was studied in an autoimmune animal model in mouse using four different ways to administer the drug – intranasally (in the nose), sublingually (under the tongue), subcutaneously (under the skin) and intradermally (in the skin) – in nine mice per group. The study showed that the four routes gave equally good results.

Regarding dose-response for Toleranzia’s tolerogen, the clinical efficacy was studied in an autoimmune animal model in mouse at five different doses, between 0.5 and 20 micrograms, in seven to nine mice per group. Hereby the dose choice that Toleranzia made in a previous study could be confirmed.

”The results of these studies are very positive as they confirm our previous work and gives us the flexibility, among several possible routes of administration, to choose the one that best promotes the development of Toleranzia’s tolerogen. The results also answer key questions that are central to the planning of future preclinical toxicology and safety pharmacology studies”, says Charlotte Fribert, CEO of Toleranzia.

For further information, please contact:
Charlotte Fribert – CEO
Phone: +46 763 19 98 98
Email: charlotte.fribert@toleranzia.com

About the company
Toleranzia AB (556877-2866) has developed a platform technology for treatment of autoimmune diseases. The company´s main project is directed towards an autoimmune neuromuscular disease, myasthenia gravis, with a significant need for an effective treatment and an extensive market potential, for which Toleranzia has been granted Orphan Drug Designation in both EU and US. The platform technology enables development of therapies that target the root cause of the disease – not just the symptoms, which is the mainstay of current treatment. In addition to myasthenia gravis, the platform technology has been evaluated in three further disease indications – rheumatoid arthritis, multiple sclerosis and type 1 diabetes, where positive treatment effects have been obtained in disease-relevant animal models. Toleranzia was founded by researchers at the University of Gothenburg. The company has operations at the Biotech center in Gothenburg. Further reading at: www.toleranzia.com.